FDA finalizes guidance on validating diagnostic tests for emerging pathogens during declared emergency. Allows developers to ...
A breakthrough therapy designation and urgent unmet need drove a three-tier rolling review for bulevirtide, allowing Gilead ...
Olympus posted JPY269.2bn ($1.7bn) in Q2 revenue, up 9% reported but only 1% in constant currency, as FDA import alerts ...
The 2027 Medicare Physician Fee Schedule final rule revises remote monitoring payments, establishes pricing for 14 ...
The German drugmaker won US FDA approval for the CSF-1R inhibitor for tenosynovial giant cell tumor, where it will compete ...
Regulatory consultant Bethany Dean of Taylored Consultancy outlines six steps cosmetics companies should take to comply with ...
Novo agrees that once provided, Medicare coverage of GLP-1s and other weight-loss drugs will be "politically" difficult to ...
The Pink Sheet’s Drug Review Profile looks at the key development and review milestones for bulevirtide in hepatitis D, ...
Ortho-phthalates could be next in line for regulatory action by California’s Department of Toxic Substances Control, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results